RBR. M. Bertina

R. M. Bertina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


R. M. Bertina has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Jeroen Eikenboom

    Division of Thrombosis and Hemostasis, Department of Internal Medicine, Einthoven Laboratory for Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, The Netherlands

    2 shared publications
  • F. R. Rosendaal

    From the Hemostasis and Thrombosis Research Center (P.W.K., F.R.R., J.C.J.E., R.M.B.) and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Center, and the Gaubius Laboratory (R.B.), TNO Prevention and Health, Leiden, the Netherlands. Dr Bos is now at Pharming Technologies, Leiden, the Netherlands

    1 shared publication
  • Francesco Rodeghiero

    The Hematology Project Foundation Department of Cell Therapy and Hematology, San Bortolo Hospital Vicenza Italy

    1 shared publication
  • Giancarlo Castaman

    Department of Cell Therapy and Hematology, Hemophilia and Thrombosis Center, San Bortolo Hospital, Vicenza, Italy

    1 shared publication
  • P. W. Kamphuisen

    Hemostasis and Thrombosis Research Center, Department of Clinical Epidemiology, Leiden University Medical Center, The Netherlands

    1 shared publication
  • R. Bos

    From the Hemostasis and Thrombosis Research Center (P.W.K., F.R.R., J.C.J.E., R.M.B.) and the Department of Clinical Epidemiology (F.R.R.), Leiden University Medical Center, and the Gaubius Laboratory (R.B.), TNO Prevention and Health, Leiden, the Netherlands. Dr Bos is now at Pharming Technologies, Leiden, the Netherlands

    1 shared publication

Latest Publications

  • Factor V Antigen Levels and Venous Thrombosis

    by P. W. Kamphuisen, F. R. Rosendaal, J. C. J. Eikenboom, R. Bos, R. M. Bertina

    —Clotting factor V has a dual function in coagulation: after activation, procoagulant factor V stimulates the formation of thrombin, whereas anticoagulant factor V acts as a cofactor for activated protein C (APC) in the degradation of factor VIII/VIIIa, thereby reducing thrombin formation. In the present study, we evaluated whether plasma factor V levels, either decreased or increased, are associated with venous thrombosis. High procoagulant factor V levels may enhance prothrombinase activity and increase the thrombosis risk. Low anticoagulant factor V levels could reduce APC-cofactor activity in the factor VIII inactivation (APC-resistant phenotype), which might also promote thrombosis. Low factor V levels in combination with factor V Leiden could lead to a more severe APC-resistant phenotype (pseudohomozygous APC resistance). To address these issues, we have measured factor V antigen (factor V:Ag) levels in 474 patients with thrombosis and 474 control subjects that were part of the Leiden Thrombophilia Study (LETS). Factor V:Ag levels increased by 7.6 U/dL for every successive 10 years of age. Mean factor V:Ag levels were 134 (range 41 to 305) U/dL in patients and 132 (range 47 to 302) U/dL in controls. Neither high nor low factor V:Ag levels were associated with venous thrombosis. We found that factor V:Ag and factor VIII antigen levels in plasma were correlated, but factor V did not modify the thrombotic risk of high factor VIII levels. The normalized APC ratio was not influenced by the factor V:Ag level in subjects with or without factor V Leiden. We conclude that neither low nor high factor V:Ag levels are associated with venous thrombosis and that factor V:Ag levels do not mediate the thrombotic risk associated with high factor VIII levels.


    • 1 September 1999
      • Vol. 82  (3) , 1065-70

    Inconsistency of association between type 1 von Willebrand disease phenotype and genotype in families identified in an epidemiological investigation.

    by G Castaman, J C Eikenboom, R M Bertina, F Rodeghiero

    In a previous epidemiological investigation among schoolchildren of Northern Italy, a conservative 1% prevalence of type 1 von Willebrand disease (VWD) was found. Diagnosis was based on a positive family history and low von Willebrand factor (VWF) ristocetin cofactor activity. To investigate whether the type 1 VWD phenotype as detected by our original methodology cosegregates with one or more specific alleles of the VWF gene, we have performed genotype analysis in affected subjects and their family members. Eleven of the 14 subjects previously identified as having VWD, all with mild personal bleeding symptoms, agreed to participate in the genetic study. Remarkably, the laboratory measurements of the previous investigation were completely confirmed in 10 of the 11 subjects. Clear cosegregation of the VWD type 1 and a specific VWF allele was observed in one family and was likely in the family of two other pro-bands. In three additional propositi and their families a possible association of the phenotype with a VWF allele was found. No association was observed in the remaining five subjects and their families. During 13-year follow-up few additional bleeding episodes were recorded among investigated subjects, most often occurring in the one family manifesting clear cosegregation. The results of this study illustrate that a personal and family bleeding history and persistently low VWF ristocetin cofactor activity, fitting the usual criteria for type 1 VWD, may not cosegregate with genetic markers at the VWF gene locus. Thus the prevalence of VWD defined as a disorder involving the VWF locus might be overestimated in population study. However, phenotypic diagnosis still remains fundamental to identify patients at risk of bleeding. Further research should clarify whether in families with more severe clinical and laboratory phenotype a clear association with markers of VWF is found.